Alembic Pharmaceuticals Ltd vs Divis Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 754.5 as of 30 Apr 15:30 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 69.8 on March 2025 . This represents a CAGR of 7.51% over 5 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 153257 crore on March 2025 . This represents a CAGR of 9.72% over 5 years The revenue of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 1891 crore as compare to the Sep '25 revenue of ₹ 1918 crore. This represent the decline of -1.39% The revenue of Divis Laboratories Ltd for the Dec '25 is ₹ 2692 crore as compare to the Sep '25 revenue of ₹ 2860 crore. This represent the decline of -5.87% The ebitda of Alembic Pharmaceuticals Ltd for the Dec '25 is ₹ 264.93 crore as compare to the Sep '25 ebitda of ₹ 324.02 crore. This represent the decline of -18.24% The ebitda of Divis Laboratories Ltd for the Dec '25 is ₹ 904 crore as compare to the Sep '25 ebitda of ₹ 1033 crore. This represent the decline of -12.49% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 131.95 crore over 7 quarters. This represents a CAGR of -1.10% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 583 crore over 7 quarters. This represents a CAGR of 19.00% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 35.99 % on March 2025 . This represents a CAGR of 5.79% over 5 years .

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
The company is engaged in pharmaceuticals business.
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
It is among the largest pharmaceutical companies in India with a portfolio of approx.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Divis Laboratories Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 14,830 Cr while Market cap of Divis Laboratories Ltd is 172,696 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Divis Laboratories Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Divis Laboratories Ltd?

As of May 4, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹754.5. On the other hand, Divis Laboratories Ltd stock price is INR ₹6505.35.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.